These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

192 related items for PubMed ID: 34563187

  • 1. The effect of treatment with pimobendan in dogs with preclinical mitral valve disease - a placebo-controlled double-blinded crossover study.
    Klein S, Nolte I, Rumstedt K, Sehn M, Raue JF, Weiner F, Treese JS, Beyerbach M, Bach JP.
    BMC Vet Res; 2021 Sep 25; 17(1):310. PubMed ID: 34563187
    [Abstract] [Full Text] [Related]

  • 2. Effect of Pimobendan on NT-proBNP and c troponin I before and after a submaximal exercise test in dogs with preclinical mitral valve disease without cardiomegaly - a randomised, double-blinded trial.
    Iwanuk N, Nolte I, Wall L, Sehn M, Raue J, Pilgram A, Rumstedt K, Bach JP.
    BMC Vet Res; 2019 Jul 09; 15(1):237. PubMed ID: 31288807
    [Abstract] [Full Text] [Related]

  • 3. Effect of pimobendan on physical fitness, lactate and echocardiographic parameters in dogs with preclinical mitral valve disease without cardiomegaly.
    Iwanuk N, Wall L, Nolte I, Raue J, Rumstedt K, Pilgram A, Sehn M, Rohn K, Bach JP.
    PLoS One; 2019 Jul 09; 14(10):e0223164. PubMed ID: 31581204
    [Abstract] [Full Text] [Related]

  • 4. Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study-A Randomized Clinical Trial.
    Boswood A, Häggström J, Gordon SG, Wess G, Stepien RL, Oyama MA, Keene BW, Bonagura J, MacDonald KA, Patteson M, Smith S, Fox PR, Sanderson K, Woolley R, Szatmári V, Menaut P, Church WM, O'Sullivan ML, Jaudon JP, Kresken JG, Rush J, Barrett KA, Rosenthal SL, Saunders AB, Ljungvall I, Deinert M, Bomassi E, Estrada AH, Fernandez Del Palacio MJ, Moise NS, Abbott JA, Fujii Y, Spier A, Luethy MW, Santilli RA, Uechi M, Tidholm A, Watson P.
    J Vet Intern Med; 2016 Nov 09; 30(6):1765-1779. PubMed ID: 27678080
    [Abstract] [Full Text] [Related]

  • 5. Short-term hemodynamic and neuroendocrine effects of pimobendan and benazapril in dogs with myxomatous mitral valve disease and congestive heart failure.
    Häggström J, Lord PF, Höglund K, Ljungvall I, Jöns O, Kvart C, Hansson K.
    J Vet Intern Med; 2013 Nov 09; 27(6):1452-62. PubMed ID: 24128373
    [Abstract] [Full Text] [Related]

  • 6. Longitudinal analysis of quality of life, clinical, radiographic, echocardiographic, and laboratory variables in dogs with myxomatous mitral valve disease receiving pimobendan or benazepril: the QUEST study.
    Häggström J, Boswood A, O'Grady M, Jöns O, Smith S, Swift S, Borgarelli M, Gavaghan B, Kresken JG, Patteson M, Åblad B, Bussadori CM, Glaus T, Kovačević A, Rapp M, Santilli RA, Tidholm A, Eriksson A, Belanger MC, Deinert M, Little CJ, Kvart C, French A, Rønn-Landbo M, Wess G, Eggertsdottir A, Lynne O'Sullivan M, Schneider M, Lombard CW, Dukes-McEwan J, Willis R, Louvet A, DiFruscia R.
    J Vet Intern Med; 2013 Nov 09; 27(6):1441-51. PubMed ID: 24010489
    [Abstract] [Full Text] [Related]

  • 7. Longitudinal Analysis of Quality of Life, Clinical, Radiographic, Echocardiographic, and Laboratory Variables in Dogs with Preclinical Myxomatous Mitral Valve Disease Receiving Pimobendan or Placebo: The EPIC Study.
    Boswood A, Gordon SG, Häggström J, Wess G, Stepien RL, Oyama MA, Keene BW, Bonagura J, MacDonald KA, Patteson M, Smith S, Fox PR, Sanderson K, Woolley R, Szatmári V, Menaut P, Church WM, O'Sullivan ML, Jaudon JP, Kresken JG, Rush J, Barrett KA, Rosenthal SL, Saunders AB, Ljungvall I, Deinert M, Bomassi E, Estrada AH, Fernandez Del Palacio MJ, Moise NS, Abbott JA, Fujii Y, Spier A, Luethy MW, Santilli RA, Uechi M, Tidholm A, Schummer C, Watson P.
    J Vet Intern Med; 2018 Jan 09; 32(1):72-85. PubMed ID: 29214723
    [Abstract] [Full Text] [Related]

  • 8. Effect of pimobendan on the incidence of arrhythmias in small breed dogs with myxomatous mitral valve degeneration.
    Lake-Bakaar GA, Singh MK, Kass PH, Griffiths LG.
    J Vet Cardiol; 2015 Jun 09; 17(2):120-8. PubMed ID: 26007710
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of pimobendan and N-terminal probrain natriuretic peptide in the treatment of pulmonary hypertension secondary to degenerative mitral valve disease in dogs.
    Atkinson KJ, Fine DM, Thombs LA, Gorelick JJ, Durham HE.
    J Vet Intern Med; 2009 Jun 09; 23(6):1190-6. PubMed ID: 19780931
    [Abstract] [Full Text] [Related]

  • 10. Effect of standard-dose and high-dose pimobendan on select indices of renal and cardiac function in dogs with American College of Veterinary Internal Medicine stage B2 myxomatous mitral valve disease.
    Kaplan JL, Visser LC, Gunther-Harrington CT, Ontiveros ES, Wittenburg LA, Palm CA, Stern JA.
    J Vet Intern Med; 2022 Nov 09; 36(6):1892-1899. PubMed ID: 36098206
    [Abstract] [Full Text] [Related]

  • 11. Effect of pimobendan on left atrial function in dogs with preclinical myxomatous mitral valve disease.
    Sarcinella F, Neves J, Maddox TW, Hodgkiss-Geere HM, Bode EF, Dukes-McEwan J.
    Open Vet J; 2020 Jan 09; 9(4):375-383. PubMed ID: 32042661
    [Abstract] [Full Text] [Related]

  • 12. Acute Effects of Pimobendan on Cardiac Function in Dogs With Tachycardia Induced Dilated Cardiomyopathy: A Randomized, Placebo-Controlled, Crossover Study.
    Abbott-Johnson K, Pierce KV, Roof S, Del Rio CL, Hamlin R.
    Front Vet Sci; 2021 Jan 09; 8():646437. PubMed ID: 34277749
    [Abstract] [Full Text] [Related]

  • 13. Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: the QUEST study.
    Häggström J, Boswood A, O'Grady M, Jöns O, Smith S, Swift S, Borgarelli M, Gavaghan B, Kresken JG, Patteson M, Ablad B, Bussadori CM, Glaus T, Kovacević A, Rapp M, Santilli RA, Tidholm A, Eriksson A, Belanger MC, Deinert M, Little CJ, Kvart C, French A, Rønn-Landbo M, Wess G, Eggertsdottir AV, O'Sullivan ML, Schneider M, Lombard CW, Dukes-McEwan J, Willis R, Louvet A, DiFruscia R.
    J Vet Intern Med; 2008 Jan 09; 22(5):1124-35. PubMed ID: 18638016
    [Abstract] [Full Text] [Related]

  • 14. Compounded pimobendan for canine chronic degenerative mitral valve disease and pulmonary hypertension.
    Helms SR, Fox S, Mixon W, Vail J.
    Int J Pharm Compd; 2012 Jan 09; 16(1):34-41. PubMed ID: 23050309
    [Abstract] [Full Text] [Related]

  • 15. Factors associated with disease progression in dogs with presumed preclinical degenerative mitral valve disease attending primary care veterinary practices in the United Kingdom.
    Mattin MJ, Brodbelt DC, Church DB, Boswood A.
    J Vet Intern Med; 2019 Mar 09; 33(2):445-454. PubMed ID: 30565334
    [Abstract] [Full Text] [Related]

  • 16. Clinical efficacy of pimobendan versus benazepril for the treatment of acquired atrioventricular valvular disease in dogs.
    Lombard CW, Jöns O, Bussadori CM.
    J Am Anim Hosp Assoc; 2006 Mar 09; 42(4):249-61. PubMed ID: 16822763
    [Abstract] [Full Text] [Related]

  • 17. Evaluation of new and old biomarkers in dogs with degenerative mitral valve disease.
    Klein S, Nolte I, Granados-Soler JL, Lietz P, Sehn M, Raue JF, Rohn K, Packeiser EM, Bach JP.
    BMC Vet Res; 2022 Jul 02; 18(1):256. PubMed ID: 35780161
    [Abstract] [Full Text] [Related]

  • 18. Efficacy of pimobendan in the prevention of congestive heart failure or sudden death in Doberman Pinschers with preclinical dilated cardiomyopathy (the PROTECT Study).
    Summerfield NJ, Boswood A, O'Grady MR, Gordon SG, Dukes-McEwan J, Oyama MA, Smith S, Patteson M, French AT, Culshaw GJ, Braz-Ruivo L, Estrada A, O'Sullivan ML, Loureiro J, Willis R, Watson P.
    J Vet Intern Med; 2012 Jul 02; 26(6):1337-49. PubMed ID: 23078651
    [Abstract] [Full Text] [Related]

  • 19. DELay of Appearance of sYmptoms of Canine Degenerative Mitral Valve Disease Treated with Spironolactone and Benazepril: the DELAY Study.
    Borgarelli M, Ferasin L, Lamb K, Bussadori C, Chiavegato D, D'Agnolo G, Migliorini F, Poggi M, Santilli RA, Guillot E, Garelli-Paar C, Toschi Corneliani R, Farina F, Zani A, Dirven M, Smets P, Guglielmini C, Oliveira P, Di Marcello M, Porciello F, Crosara S, Ciaramella P, Piantedosi D, Smith S, Vannini S, Dall'Aglio E, Savarino P, Quintavalla C, Patteson M, Silva J, Locatelli C, Baron Toaldo M.
    J Vet Cardiol; 2020 Feb 02; 27():34-53. PubMed ID: 32032923
    [Abstract] [Full Text] [Related]

  • 20. Current use of pimobendan in canine patients with heart disease.
    Boswood A.
    Vet Clin North Am Small Anim Pract; 2010 Jul 02; 40(4):571-80. PubMed ID: 20610012
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.